Kornimate/medical-research-clean huggingface dataset:
preoperative imrt with concurrent high-dose vitamin c and mfolfox6 in locally advanced rectal cancer

Conditions: Rectal Cancer

Summary: the purpose of this study is to evaluate the safety and efficacy of preoperative chemoradiotherapy (imrt) with concurrent high-dose intravenous vitamin c and mfolfox6 in locally advanced rectal cancer patients.

sixty patients with locally advanced rectal cancer (ct3-4n0m0, ct1-4n1-2m0, ≤12cm from anus) will be enrolled and receive preoperative imrt concurrent with high-dose intravenous vitamin c and 2-3 cycles of mfolfox6 chemotherapy, and then after 4 weeks rest, they will continue to complete 3 cycles of preoperative chemotherapy (mfolfox6). radical surgery will be performed at 10-12 weeks after imrt. in this study, we will evaluate the safety and effectiveness of the treatment method through the acute toxicity \[during crt (concurrent chemoradiotherapy )\], pcr (pathologic complete response) rate, sphincter preserving surgery rate, 2-year survival rate and 2-year disease-free survival rate.

Eligibility criteria:
inclusion criteria: 1. 18 to 75 years of age with a confirmed histopathologic diagnosis of adenocarcinoma of the rectum and considered suitable for curative resection. 2. tumors were clinically confirmed (by mri or ct plus endorectal ultrasound) as stage ii (ct3-4n0) or stage iii (ct1-4n1-2), with a positive node defined as ≥1.0 cm in diameter on imaging) and a distal border located , 12 cm from the anal verge. 3. patients were required to have an eastern cooperative oncology group performance status ≤ 1 and adequate hematologic, liver, and renal function. (hgb≥90g/l, wbc≥3.5×10\^9/l, plt≥90×10\^9/l；alt / ast≤2.5× uln；t bill≤1.5×uln，cr ≤1.5×uln) 4. laboratory examination showed that glucose-6-phosphate dehydrogenase (g6pd) was normal. 5. the patient agreed and had signed the informed consent exclusion criteria: 1. with metastatic disease. 2. prior radiotherapy or chemotherapy. 3. the presence of other cancers. 4. clinically significant cardiac disease. 5. known peripheral neuropathy. 6. with intestinal obstruction, intestinal perforation or tumor bleeding who need emergency operation. 7. rectal cancer with signet-ring cell carcinoma, or with neuroendocrine tumor.

Keywords: rectal cancer neoadjuvant chemoradiotherapy vitamin c
acupuncture of different treatment frequency on improving quality of life in patients with functional dyspepsia

Conditions: Functional Dyspepsia

Summary: the objective of this trial is to assess acupuncture of different treatment frequency on improving quality of life in patients with functional dyspepsia.

the effect of treatment frequency of acupuncture on the functional dyspepsia is unclear. in this study, 60 participants with fd will be recruited and randomly allocated (using a 1:1:1 allocation ratio) into three times a week group, once a week group and waiting for treatment group. participants will receive acupuncture treatment at bilateral zhongwan（cv12）, tianshu（st25）, neiguan（pc6）, liangqiu（st34）, yanglinquan（gb34）, zusanli（st36）and taichong（lr3) of different treatment frequency for 4 weeks. this trial is designed to analyze the acupuncture of different treatment frequency on improving quality of life in patients with fd and to provide evidence for the establishment of acupuncture treatment quantization standard of fd.

Eligibility criteria:
inclusion criteria: 1. diagnosis of fd as defined by the roman iv functional dyspepsia diagnostic criteria one or more of the following: 1. bothersome postprandial fullness 2. bothersome early satiation 3. bothersome epigastric pain 4. bothersome epigastric burning and no evidence of structural disease (including at upper endoscopy) that is likely to explain the symptoms epigastric pain syndrome (eps) criteria: fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis. postprandial distress syndrome diagnostic (pds) criteria: must include one or both of the following at least 3 days per week: 2. age 18-75 years. 3. signed informed consent and volunteered to participate in the trial. exclusion criteria: candidate participants with any of the following items will be excluded from this trial. 1. gastrointestinal motility drugs taken within the past 15 days; acupuncture treatments within the past 30 days; participating in other ongoing clinical trials 2. severe heart, lung, liver, brain or kidney damage. 3. would-be mothers, pregnant or lactation; 4. progressive malignant tumor or other severe consumptive diseases, easy to be complicated with bleeding and infection; 5. cognitive impairment such as unable to express subjective symptoms of discomfort or give informed consent.
built-in calculator optimizes continuous veno-venous hemofiltration prescription and improves therapeutic quality in critically-ill acute kidney injury patients

Conditions: CVVH; Filtration Fraction; Built-in Culculator

Summary: the goal of this observational study is to compare in icu patients received cvvh treatment. the main questions it aims to answer are: control of filtration fraction by built-in calculator * reduced filter clotting and prolong filter lifespan * improve patient mortality participants will divided into before group and after group based on the day when built-in calculator for calculating filtration fraction was utilized. researchers will compare before group to see if there were differences in clotting events, filter downtime, filter lifespan, mortality, etc.

# built-in calculator for calculating filtration fraction * the calculator was built in prescription system since 2020/10/01 * providing tempt filtration fraction for operators to adjust cvvh dose * the protocol of patient care didn't change between before and after group.

Eligibility criteria:
inclusion criteria: * icu patients received cvvh during 2019\~2021 (3 years) in our hospital exclusion criteria: * under age of 20, pregnant, or with hiv infection
molecular analysis of 150 lung adenocarcinoma

Conditions: Lung Adenocarcinoma

Summary: lung-est is a retrospective study including 152 patients who benefit from lung surgery during the years 2012 to 2013 at hospices civils de lyon and with a diagnosis of lung adenocarcinomas. for all patients, clinical data and histopathological data are available. the objective of this study is to characterize these lung adenocarcinomas by the lungcarta panel using the mass spectrometry array sequenom. this panel could identify 214 dna mutations and/or frameshift insert/deletion among 26 oncogenes. once included in the study, the adenocarcinomas are also included in a tissue microarray (tma) in order to perform immunohistochemical analysis. immunohistochemical staining with innovative antibodies are correlated with clinical, histopathological and molecular data. our hypothesis is that this tma could constitute a good tool to screen interesting protein's expression.


Eligibility criteria:
inclusion criteria: * adults * lung adenocarcinoma * surgical specimen exclusion criteria: * not adenocarcinoma subtype of lung cancer * tumour biopsy * insufficient material for dna extraction

Keywords: lungcarta panel lung adenocarcinoma
ai-augmented skin cancer diagnosis in teledermatoscopy

Conditions: Skin Cancer; Melanoma

Summary: in this study an artificial intelligence (ai) tool for skin cancer diagnosis is implemented in a teleldermatoscopy platform. the aim is to study the effects on clinician diagnostic accuracy, management decisions, and confidence. furthermore, this prospective randomized study investigates the role of human factors in determining clinician reliance on ai tools and the consequent accuracy in a real-world setting.

deep-learning algorithms can potentially benefit many areas in healthcare, including the diagnosis of skin cancer using teledermatoscopy. however, there is a dearth of clinical, prospective research on human-ai interaction in diagnostic tasks that take human factors into account. in this study we will examine the impact of such factors in a real-world setting where we integrate an algorithm in an existing teledermatoscopy platform that is used clinically at a tertiary hospital in sweden. we will investigate what impact various implementations of ai tool output in relation to human factors have on diagnostic accuracy and management decisions. study subjects are recruited at the department of dermatology at karolinska university hospital and will be asked to rate prospective teledermatoscopic consults with and without ai-support. each consult will be randomized into one of three workflows with or without one pre-defined implementation of the ai tool. study subjects are also asked to complete two surveys with demographic information and questions relating to various human factors. patients participating in the study will be diagnosed outside the study prior to inclusion without any involvement of an ai tool, notably by two experienced dermatologists who do not participate as study subjects.

Eligibility criteria:
inclusion criteria: * licensed physician * working at a dermatology clinic * sufficient knowledge in swedish * written consent to participate exclusion criteria: * no experience of using dermatoscopy * does not wish to participate * incomplete answers * physicians that are involved in the patients' clinical care relating to the teledermoscopical consult

Keywords: melanoma artificial intelligence ai augmentation deep learning teledermatoscopy dermatoscopy skin cancer
precision medicine study on cardiovascular disease (precise)

Conditions: Cardiovascular Diseases

Summary: cardiovascular diseases are the leading cause of death in china and have become a financial burden on society under the traditional medical model. a new and sustainable medical model is needed to solve this dilemma, for which precision medicine models have great potential. monogenic cardiovascular disease is the first field to be broken through in precision medicine at this stage, and it is also the field where precision medicine is most likely to be successfully transformed into clinical application, including genetic diagnosis, molecular typing, risk stratification, genetic interruption and individualized treatment.

in this study, patients with monogenic cardiovascular disease are recruited prospectively after informed consent was given. the investigator will collect the baseline clinical characteristics of the patients at enrollment, including comprehensive physical examination, laboratory testing of blood and urine, electrocardiography, 24-hour holter, echocardiography, mri and other examinations if necessary. the specimens retained include blood, saliva, urine and feces for all patients, and myocardium for patients receive cardio myectomy surgery . genetic testing will be performed to identify novel disease genes, genetic risk factors and potential therapy targets.

Eligibility criteria:
inclusion criteria: * patients with monogenic cardiovascular diagnosed according current practice guideline. exclusion criteria: * patients who refuse to sign the informed consent or decline follow-up.

Keywords: monogenic cardiovascular disease clinical outcomes genomics genetic diagnosis risk stratification
bardet-biedl syndrome study: clinical and genetic epidemiology study in adults

Conditions: Bardet-Biedl Syndrome; Orphan Diseases

Summary: this study is based on the study of the natural history of a rare disorder: the bardet-biedl syndrome (bbs) (which is associated with retinitis pigmentosa, polydactyly, cognitive impairment, obesity, and kidney failure). the clinical, biological, and radiological features of adult patients are studied. in parallel, a molecular study is performed on the known genes to date (8 genes from bbs1 to bbs8) and to identify new genes involved. the parts of the study are combined in a phenotype-genotype correlation study.


Eligibility criteria:
inclusion criteria: * adult (age over 16 years old) * at least 3 of the five major criteria (retinitis pigmentosa, obesity, polydactyly, cognitive impairment, and kidney disorder) and/or bbs mutations identified

Keywords: bardet-biedl syndrome, retinitis pigmentosa, obesity, genes
three birds with one stone

Conditions: Uterine Cervical Cancer; Uterine Cervix Cancer; Uterine Cervical Neoplasm; Colorectal Neoplasms; Colorectal Cancer; Colorectal Carcinoma; Mass Screening; Early Detection of Cancer

Summary: the overall aim of the study is to increase participation rates in cervical cancer (ccu) and colorectal cancer (crc) screening programmes in denmark by offering home-based ccu and crc screening to women who are overdue for one or both screening programmes when attending breast cancer screening

a cluster-randomised public health trial will take place in central denmark region (cdr) targeting women attending breast cancer screening. five breast cancer screening units serve women five days a week, and all five units will be included in the study and randomly allocated to an equal amount of intervention days. on the intervention days, the other four units will serve as the control group, providing a randomisation ratio of 1:4. on the intervention days, a research assistant will ask the women aged 50-69 years if they are interested in having a check up on their screening status with ccu and crc screening. if the woman has not participated timely, she will be offered to receive a test-kit corresponding to crc screening and/or to receive a self-sample device for ccu screening (or reminded to call her general practitioner (gp) to have a conventional cervical cytology sample taken). if the woman accepts a self-sample kit for ccu and/or crc screening, she will receive it by mail together with written instructions, picturebased user instructions, information on national recommendation for cancer screening and a pre-paid, pre-addressed envelope for returning the sample to the laboratory. the result of the test will be sent to the women by digital mail as well as passed on to her gp. clinical management in case of a positive test result will follow national guidelines corresponding to ccu and crc screening programmes. women in the control group will receive standard screening offers according to the national screening programmes. all women entering a breast cancer screening unit in cdr on a intervention day (intervention + control units) will be sent a survey asking their experience with breast cancer screening a few days after breast cancer screening. the women in the intervention group will be asked about the acceptability of the intervention as well. 27500 women must be included, of which 5500 women will be in the intervention group.

Eligibility criteria:
inclusion criteria: women aged 50-69 years attending breast cancer screening in central denmark region on selected days. * in ccu screening: women aged 50-64 years will be classified as overdue if they have not had a cervical sample within the last 5 years and 6 months * in crc screening: women aged 50-69 years will be classified as overdue, if they have not had a fit within the last 2 years and 4.5 months despite an invitation.
prognosis of posterior lamellar keratoplasty, an observational cohort study

Conditions: Fuchs' Endothelial Corneal Dystrophy; Pseudophakic Bullous Keratopathy

Summary: over the past decade, the management of fuchs' endothelial corneal dystrophy (fecd) and pseudophakic bullous keratopathy (pbk) has been revolutionized by the development of posterior lamellar keratoplasty techniques: dsaek and dmek. dsaek (descemet stripping automated endothelial keratoplasty) involves replacing the patient's endothelium and pathological descemetum with a descemetic endothelial graft combined with a thin stromal lamella. the endothelial density of the grafts is generally greater than 2,400 cells/mm². depending on the grafting center and tissue bank, grafts may be either pre-cut in the tissue bank or cut on the operating table by the surgeon himself. the donor graft is placed on an artificial anterior chamber, and automated microkeratome cutting produces grafts with an average thickness of 100 to 200µm, sometimes less than 100um (known as ut-dsaek or ultra-thin dsaek). dmek (descemet membrane endothelial keratoplasty) is a strictly endothelium and descemet's membrane graft, as close as possible to the original anatomy of the cornea. the graft is dissected manually either in a tissue bank (pre-cut grafts) or on the operating table by the surgeon. the thickness of the graft is between 15 and 18 microns. the primary objective of this observational cohort is to compare the evolution of visual acuity after dmek, dsaek or ut-dsaek transplantation. secondary objectives are to compare the evolution of endothelial cell density, corneal thickness and early and late post-operative complications, and to identify factors predictive of these different endpoints.


Eligibility criteria:
inclusion criteria: * patients who received a posterior lamellar keratoplasty in metz-thionville regional hospital between 2012 and 2030 exclusion criteria: * patients refusing to take part in the study

Keywords: posterior lamellar keratoplasty cornea dmek dsaek
auricular acupuncture vs soc in migraine ha

Conditions: Migraine Headache

Summary: patients with migraine headache will be offered the opportunity to participate in this randomized study evaluating auricular acupuncture versus standard treatment for migraine headaches for patients in the pediatric emergency department (ed).

potential subjects will be identified using the diagnosis of migraine headache classified by the modified ichd-ii (international classification for headache disorders) criteria proposed by hershey et. al. this diagnosis will be confirmed by the investigators prior to enrollment of the subject and will be documented in the study documents. subjects will be recruited during the scheduled work or research hours of the investigators in the ed. eligible patients will be informed of the study including a discussion of the two possible interventions. after informed consent and assent are obtained, patients will be randomly assigned 1 of the 2 arms of the study. the target is 40 subjects in each arm. subjects will be assigned to a study group using a computer generated randomization schema. this randomization will only be known to one unblinded collaborator that will not be enrolling subjects or be involved in the data analysis. if assigned to receive intravenous migraine medications the subject will be treated with the standard of care medications which include ketorolac (0.5mg/kg, max 30mg), metoclopramide (0.1 mg/kg, max 10mg), diphenhydramine (1mg/kg, max 50mg) plus a normal saline fluid bolus (20ml/kg, max 1000ml). if assigned to the auricular acupuncture arm, efficacious ear points will be located by a needle contact test and/or an electrical point finder which emits an acoustic alarm when a change in electrical resistance is detected signifying a potential active auricular acupoint. if the subject does not improve with acupuncture, they will be assessed by the ed physician and at the md discretion further emergency department treatment will be administered which may include intravenous migraine medications as this is the current standard of care in the norton children's hospital/norton children's medical center (kch/kcmc) ed. all subjects will be contacted 2 to 6 days after discharge to determine their clinical status. if the darts are still in place at the follow-up call, the subjects will be contacted at 2 weeks and weekly thereafter until all darts have fallen out.

Eligibility criteria:
inclusion criteria: * confirmation of the diagnosis of migraine headache exclusion criteria: * patients who received ed migraine medications (including ibuprofen or other nsaids) prior to study evaluation. * allergy to any of the medications used in our migraine regimen protocol. * patients exhibiting focal clinical neurological exam findings that the investigator deems makes the patient not a good candidate for this study. * patients with underlying abnormal brain pathology (e.g. mass or bleed) as the potential cause of the migraine

Keywords: migraine headache acupuncture
a study of adh-1 in combination with normothermic isolated limb infusion of melphalan

Conditions: Neoplasms

Summary: n-cadherin, a protein involved in blood vessel cell binding and on the surface of many tumor cells, is increased as cancer progresses. adh-1 blocks n-cadherin. this study will test the safety and effects of the combination adh-1 with normothermic isolated limb infusion of melphalan in subjects with locally advanced malignant melanoma.


Eligibility criteria:
inclusion criteria: * signed written informed consent * male and female patients \> or = 18 years of age with diagnosis of melanoma for which treatment with normothermic isolated limb infusion (ili) of melphalan would be appropriate * measurable disease * disease site(s) must be distal to the planned site of tourniquet placement * available for immunohistochemical testing of n-cadherin expression tumor tissue * adequate performance status and organ function, as evidenced by hematological and biochemical blood testing and ecg exclusion criteria: * receipt of adh-1 prior to this clinical study (prior melphalan via ili, is okay) * stage iv melanoma * chemotherapy, radiotherapy, or any other investigational drug within 4 weeks before study entry * history of tumors that have shown clinically significant evidence of active bleeding within 12 weeks before study entry * stroke, major surgery, or other major tissue injury within 4 weeks before study entry * uncontrolled congestive heart failure, coronary artery disease, or life threatening arrhythmias; myocardial infarction within 12 months; significant electrocardiogram (ecg) abnormalities * allergic reaction to any therapeutic peptide or to melphalan

Keywords: cancer tumors melanoma anticarcinogenic agents antineoplastic agents cadherins solid tumors
patient-reported outcome measures (proms) in patients with bodily stress syndrome: protocol for a prospective cohort study

Conditions: Fibromyalgia; Irritable Bowel Syndrome; Somatic Symptom; Chronic Fatigue Syndrome; Fatigue; Dysphagia; Exhaustion; Syndrome

Summary: this cohort study implements patient reported outcome measures (proms) for patients with bodily stress syndrome in a clinic for functional disorders.

the sympa cohort study is a prospective, single site cohort study that consists of administration of proms questionnaires to patients that attend the clinic for functional disorders at helsinki university hospital (hus). the questionnaires are handed out to the study population within seven days before their first visit at the clinic, and then at the following 3, 6 and 12 months. the study population consists of consecutive adult patients that are referred to the clinic either from other hospital units or primary care. the collected data will later be linked with national registries on diagnoses, medication use and work ability. the sympa cohort study may have implications in targeting the factors influencing functional outcomes and quality of life reported by patients with bodily stress syndrome. it will also form a quality register for the clinic and characterize the first systematic collection of proms related to these disorders in finland.

Eligibility criteria:
inclusion criteria: * all genders * age 18-80 years * referred to clinic for functional disorders either from other hospital units or from primary care * willingness to be enrolled in the study, by signing the informed consent exclusion criteria: * patients not able to fill in the forms in finnish or due to physical constraints (e.g. dystonia) * symptoms are likely due to a somatic disorder

Keywords: bodily stress syndrome functional somatic symptoms functional somatic syndrome